Mar 23 2012
Endo (Nasdaq: ENDP) announced today that it has acquired U.S. patent 7,851,482 B2 for oxymorphone hydrochloride, the key API in all formulations of OPANA, from Johnson Matthey plc. Johnson Matthey is a leading supplier of active pharmaceutical ingredients through its worldwide Fine Chemicals Division.
By acquiring Johnson Matthey's patent to the oxymorphone ingredient, which will be listed in the U.S. Food and Drug Administration's Orange Book, Endo will enjoy additional patent protection for its OPANA franchise, now through 2029.
"This patent not only covers our newly designed to be crush resistant OPANA® ER, it covers all products that include oxymorphone that are manufactured in accordance with current FDA specifications," said Julie McHugh, chief operating officer of Endo.